139 related articles for article (PubMed ID: 37031440)
1. [Alectinib and mixed large cell neuroendocrine carcinoma of the lung.].
Hegedűs F; Sükösd F; Tiszlavicz L; Furák J; Pálföldi R; Fejes Z; Zombori T
Orv Hetil; 2023 Apr; 164(14):548-554. PubMed ID: 37031440
[TBL] [Abstract][Full Text] [Related]
2. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
3. A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib.
Lim CA; Banyi N; Tucker T; Ionescu DN; Melosky B
Curr Oncol; 2022 Feb; 29(2):848-852. PubMed ID: 35200571
[TBL] [Abstract][Full Text] [Related]
4. Use of ALK Immunohistochemistry for Optimal Therapeutic Strategy of Pulmonary Large-cell Neuroendocrine Carcinoma and Identification of a Novel
Shimizu N; Akashi Y; Fujii T; Shiono H; Yane K; Kitahara T; Ohta Y; Kakudo K; Wakasa T
Anticancer Res; 2019 Jan; 39(1):413-420. PubMed ID: 30591488
[TBL] [Abstract][Full Text] [Related]
5. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
6. [Large-cell neuroendocrine carcinoma of the lung - challenges of diagnosis and treatment].
Zombori T; Juhász-Nagy G; Tiszlavicz L; Cserni G; Furák J; Szalontai K; Pálföldi R
Orv Hetil; 2020 Feb; 161(8):313-319. PubMed ID: 32073294
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Large-Cell Neuroendocrine Lung Carcinoma With ALK Fusion Oncogene With Partial Response to Alectinib.
Leblanc A; Owen S; Fiset PO; Gomez Corrador AL; Isenberg J; Bouganim N
JCO Precis Oncol; 2021 Nov; 5():802-807. PubMed ID: 34994612
[No Abstract] [Full Text] [Related]
8. Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer: Description of 2 case reports.
Gozzi E; Angelini F; Rossi L; Leoni V; Trenta P; Cimino G; Tomao S
Medicine (Baltimore); 2020 Jul; 99(27):e21004. PubMed ID: 32629718
[TBL] [Abstract][Full Text] [Related]
9. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
10. Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
Wang S; Wu X; Zhao J; Chen H; Zhang Z; Wang M; Xu C; Wang Y; Wang L; He Z; Wang Q
Clin Lung Cancer; 2021 May; 22(3):e366-e370. PubMed ID: 32651063
[No Abstract] [Full Text] [Related]
11. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CD 133 and BCL-2 in non-small cell lung cancer with neuroendocrine differentiation after transformation in ALK rearrangement-positive adenocarcinoma.
Koyama K; Katsurada N; Jimbo N; Tachihara M; Tamura D; Nakata K; Nagano T; Yamamoto M; Kamiryo H; Kobayashi K; Itoh T; Nishimura Y
Pathol Int; 2019 May; 69(5):294-299. PubMed ID: 30900377
[TBL] [Abstract][Full Text] [Related]
13. Alectinib Treatment of ALK Positive Non Small Cell Lung Cancer Patients with Brain Metastases: Our Clinical Experience.
Crvenkova S
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Sep; 41(2):29-36. PubMed ID: 33011694
[TBL] [Abstract][Full Text] [Related]
14. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with
Tashiro T; Imamura K; Tomita Y; Tamanoi D; Takaki A; Sugahara K; Sato R; Saruwatari K; Sakata S; Inaba M; Ushijima S; Hirata N; Sakagami T
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352665
[TBL] [Abstract][Full Text] [Related]
17. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
Nitawaki T; Sakata Y; Kawamura K; Ichikado K
BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
[TBL] [Abstract][Full Text] [Related]
18. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and HIP1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
20. Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.
Lin J; Wang W; Lin J; Chen R; Cao Y
J Cell Mol Med; 2022 Oct; 26(20):5326-5329. PubMed ID: 36102237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]